B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers on the company’s strategy to inactivate or degrade ...

Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel. Kalpit Patel’s rating is based on Foghorn Therapeutics’ innovative approach to ...

When you buy through links on our site, we may earn an affiliate commission. Learn More When you think of a sheepdog, what comes to mind? You might envision a hearty, hardworking dog who spends its ...